Arena Pharma (ARNA) Misses Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of ($2.54), $0.28 worse than the analyst estimate of ($2.26). Revenue for the quarter came in at $54 thousand versus the consensus estimate of $660 thousand.
Cash, cash equivalents and marketable securities were $0.7 billion at December 31, 2021 as compared to $1.1 billion at December 31, 2020
For earnings history and earnings-related data on Arena Pharma (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Kotak Upgrades Thermax Ltd (TMX:IN) to Buy (1)
- Nomura/Instinet Downgrades LG Chem Ltd (051910:KS) (LGCLF) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
